<DOC>
	<DOCNO>NCT00655486</DOCNO>
	<brief_summary>The purpose study allow eligible subject parent study , SP925 [ NCT00655551 ] continue lacosamide obtain additional long-term safety data</brief_summary>
	<brief_title>Study Assess Long-term Safety Oral Lacosamide Subjects With Partial-onset Seizures</brief_title>
	<detailed_description>A multicenter , open-label extension study ass long-term safety tolerability lacosamide adjunctive therapy subject partial-onset seizure previously enrol SP925 study [ NCT00655551 ] ( intravenous lacosamide load dose follow approximately 1 week oral lacosamide maintenance ) .</detailed_description>
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies , Partial</mesh_term>
	<mesh_term>Lacosamide</mesh_term>
	<criteria>Eligible subject participate SP925 [ NCT00655551 ] treatment partialonset seizure Receiving study drug experimental device lacosamide Meets withdrawal criterion parent study SP925 [ NCT00655551 ] Experiencing ongoing serious adverse event</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Epilepsy</keyword>
	<keyword>seizure</keyword>
	<keyword>antiepileptic</keyword>
	<keyword>Lacosamide</keyword>
	<keyword>Vimpat</keyword>
	<keyword>safety</keyword>
	<keyword>adjunctive</keyword>
</DOC>